Solventum Corporation

Solventum Corporation is an American healthcare company that develops, manufactures, and commercializes medical supplies, dental products, and health information systems, generating $8.3 billion in revenue in fiscal 2025. The company was spun off from 3M in April 2024, inheriting a 70-year legacy of innovation within one of the world's most storied industrial conglomerates and roughly $8 billion of debt to go with it. Less than two years later, it has sold a division for $4 billion, paid down nearly half its debt, reorganized its global sales force, launched a multiyear cost-savings program, and begun buying back stock — all while accelerating its organic growth rate threefold from its pre-spin baseline.

This is a transformation story unfolding in real time inside a steady-state healthcare business. Solventum's underlying franchises — negative pressure wound therapy under the V.A.C. brand, I.V. site management led by Tegaderm, sterilization assurance, dental restoratives, and a revenue-cycle software platform — hold strong market positions with genuine clinical differentiation. The investment question is not whether these are good businesses; it is whether the management team that 3M's board recruited to run them can finish the separation, rebuild the operating infrastructure, and redirect the organization's energy from survival to offense before the structural headwinds of tariffs, raw-material dependency, and post-spin cost step-ups consume the margin runway.

The file turns on a single question: can Solventum reach its long-range plan targets of 4–5% organic growth and 23–25% operating margins by 2028, or does the separation from 3M exact a heavier and more lasting toll than the company's narrative allows?